Browsing by Author Wu Y.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)
1Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective studyGolder V.; Kandane-Rathnayake R.; Hoi A.; Huq M.; Louthrenoo W.; An Y.; Li Z.; Luo S.; Sockalingam S.; Lau C.; Mok M.; Lateef A.; Franklyn K.; Morton S.; Navarra S.; Zamora L.; Wu Y.; Hamijoyo L.; Chan M.; O'Neill S.; Goldblatt F.; Nikpour M.; Morand E.
20-Jul-2011Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)Fukuoka M.; Wu Y.; Thongprasert S.; Sunpaweravong P.; Leong S.; Sriuranpong V.; Chao T.; Nakagawa K.; Chu D.; Saijo N.
-Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLCWu Y.; Saijo N.; Thongprasert S.; Yang J.; Han B.; Margono B.; Chewaskulyong B.; Sunpaweravong P.; Ohe Y.; Ichinose Y.; Yang J.; Mok T.; Young H.; Haddad V.; Rukazenkov Y.; Fukuoka M.
9-Nov-2016Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohortGolder V.; Kandane-Rathnayake R.; Hoi A.; Huq M.; Louthrenoo W.; An Y.; Li Z.; Luo S.; Sockalingam S.; Lau C.; Lee A.; Mok M.; Lateef A.; Franklyn K.; Morton S.; Navarra S.; Zamora L.; Wu Y.; Hamijoyo L.; Chan M.; O'Neill S.; Goldblatt F.; Morand E.; Nikpour M.
6Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalLee C.; Davies L.; Wu Y.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; Tu Y.; Gralla R.; Gebski V.; Mok T.; Yang J.
1-Sep-2010Lung cancer working group reportSaijo N.; Fukuoka M.; Thongprasert S.; Ichinose Y.; Mitsudomi T.; Mok T.; Ohe Y.; Park K.; Wu Y.
1-Aug-2016Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerMok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Yu C.; Thongprasert S.; Sandoval-Tan J.; Lee J.; Fuerte F.; Shames D.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.